PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17332297-7	2007	Pharmacokinetic analysis at 1.3 mg/m(2) revealed a clearance of 11 mL/h/m(2), a central volume of distribution of 6.7 L/m(2), and a terminal half-life of 12.6 h. NF-kappaB activity was examined in five patients and was noted to transiently increase and then decrease 4- to 6-fold by 24 h following bortezomib in two patients.	Bortezomib	298-308	nuclear factor kappa B subunit 1	Homo sapiens	162-171	
17332297-10	2007	Although bortezomib treatment inhibited NF-kappaB activity, bortezomib had little activity as a single agent in this population.	Bortezomib	9-19	nuclear factor kappa B subunit 1	Homo sapiens	40-49